Medtronic Plc: Q1 2027 (Ended July 31, 2026) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended July 31, 2026 (Q1 of Fiscal Year 2027). Fiscal 2027 is a 53-week year, with the extra week occurring in the first quarter, providing an estimated $570 million benefit to reported growth. The Company continues the separation of its Diabetes Business into MiniMed Group, Inc. (MMED), which completed its IPO in March 2026; Medtronic retains a controlling interest (~90%), and MiniMed results remain consolidated. The Company reorganized its Cardiovascular Portfolio into four divisions: Electrophysiology Therapies (EPT), Interventional Cardiology Therapies (ICT), CardioVascular Surgery (CVS), and Peripheral Vascular Health (PVH).
Key Financial Metrics
| Metric | Q1 2027 (Jul 31, 2026) | Q1 2026 (Jul 25, 2025) | Change |
|---|---|---|---|
| Net Sales | $9,756 million | $8,578 million | +14% |
| Operating Profit | $1,764 million | $1,445 million | +22% |
| Net Income (Attributable to Medtronic) | $1,470 million | $1,040 million | +41% |
| Diluted EPS | $1.14 | $0.81 | +41% |
| Operating Cash Flow | $1,793 million | $1,088 million | +65% |
| Free Cash Flow | $1,290 million | $584 million | +121% |
| Total Debt | $28.2 billion | $28.0 billion (Apr 2026) | Minimal Change |
| Cash & Investments | $8.8 billion | $9.2 billion (Apr 2026) | -4% |
Margins: Operating margin improved to 18.1% from 16.8% in the prior year. The effective tax rate was 16.4%, down from 19.6% year-over-year, driven by the release of reserves for uncertain tax positions.
Material Changes vs. Prior Period
- Revenue Growth: Driven by organic growth across all reportable segments and the 53-week fiscal year. Cardiovascular sales grew 20% (EPT +30%), Neuroscience grew 10%, and Medical Surgical grew 10%. The Diabetes Business (non-reportable segment) grew 17%.
- Acquisitions: The Company completed two significant acquisitions in Q1: Scientia Vascular ($681 million total consideration) to expand neurovascular capabilities and SPR Therapeutics ($654 million) for peripheral nerve stimulation technology. Both are assigned to the Neuroscience Portfolio.
- Restructuring: Restructuring charges increased to $89 million from $67 million, primarily related to the MiniMed separation and organizational realignments.
- Investment Gains: Other non-operating income improved significantly due to a $64 million gain on minority investments, compared to a $113 million loss in the prior year.
Outlook, Risks, and Contingencies
- MiniMed Separation: The Company plans to complete the full separation of the Diabetes Business within Fiscal 2027. Restructuring costs associated with this separation are expected to total $300–$500 million over the transition period.
- Legal Proceedings:
- Hernia Mesh: A jury verdict of $88 million was returned in August 2026. Medtronic intends to appeal and has not recorded a liability as the loss is not deemed probable at this time.
- Applied Medical Antitrust: A jury awarded $382 million (subject to trebling) in February 2026. Medtronic plans to appeal and has not recorded a liability.
- Italian Payback: A $39 million reduction in liability was recognized in the prior year; discussions continue regarding years 2019 and beyond.
- Macroeconomic Risks: Management cites risks related to global trade policies, tariffs, currency fluctuations, and reimbursement challenges. The Company is monitoring the impact of U.S. tariff policies and potential refunds.
- Capital Allocation: Approximately $1.0 billion remains under the $5.0 billion share repurchase program. Dividends paid were $0.72 per share.
Investor Verification Checklist
- MiniMed Transition: Verify the timeline and cost certainty of the remaining separation activities and the impact on future earnings once MiniMed is fully deconsolidated.
- Legal Accruals: Monitor the status of the Hernia Mesh and Applied Medical appeals to assess the potential for future liability recognition.
- Acquisition Integration: Track the revenue contribution and integration progress of the Scientia Vascular and SPR Therapeutics acquisitions.
- Tax Rate Volatility: Confirm the sustainability of the 16.4% effective tax rate, which was aided by one-time reserve releases.
- 53-Week Impact: Adjust year-over-year growth comparisons to exclude the ~$570 million benefit from the extra week in Q1 2027 to gauge true organic performance.